Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
A published study examining appetite and eating behaviors during retatrutide treatment in the phase 2 trial found that 31 of 36 retatrutide-treated participants (86%) reported changes in eating behaviors within the first eight weeks of treatment
Some patients have genetic variations in the GLP-1 receptor gene (rs6923761), while others carry variants in the FTO gene (rs9939609) or MC4R gene (rs17782313) that influence appetite and energy storage differently
Tirzepatide (Mounjaro and Zepbound) is a dual GLP-1/GIP receptor agonist approved by the FDA for managing blood sugar levels (Mounjaro) and chronic weight management (Zepbound)
It decreases hunger, improves fullness, and helps the body use stored fat more effectively
Tirzepatide (GLP-1/GIP) Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, providing synergistic metabolic effects for diabetes and obesity research
Consistent daily timing
